Cellular 'Short Circuit' Causes Insulin Resistance

January 20, 1998

Rehovot, Israel, Janaury 20, 1998 -- Future treatments for diabetes may correct the underlying causes of this prevalent metabolic disorder rather than just treat its symptoms. An important step in this direction has been made by Prof. Yehiel Zick of the Weizmann Institute's Molecular Cell Biology Department.

In a study reported in the November 21 issue of the Journal of Biological Chemistry, Zick and colleagues provided a new insight into the molecular basis of insulin resistance, a condition that can lead to diabetes. In insulin resistance, cells no longer respond to ordinary levels of insulin. The scientists discovered that this may occur because some of the proteins that relay messages from the insulin receptor to the glucose uptake machinery in cells undergo excessive phosphorylation (a process in which they acquire phosphorus atoms). Such abnormal phosphorylation generates a "short circuit" that prevents the insulin receptors from communicating their "messages" to the cells' interior, making the cells resistant to insulin.

In addition, the new study may explain why diabetes is five times more common in obese people than in people of normal weight. According to Prof. Zick, a major culprit in enhancing the inappropriate phosphorylation is a molecule called TNF, which is secreted by fat cells. The excessive secretion of TNF by obese people may explain the link between obesity, insulin resistance and diabetes.

These findings may in the future lead to new treatments for diabetes that would be based on correcting insulin resistance.

ADDITIONAL INFORMATION

Prof. Zick's team included Ph.D. student Keren Paz, Dr. Eytan Elhanany of the Israel Institute for Biological Research, Dr. Hannah Kanety, Prof. Avraham Karasik, and Rina Hemi of the Sheba Medical Center in Tel Hashomer and Dr. Derek LeRoith of the National Institutes of Health, Bethesda, MD. This work was supported by research grants from the Kekst Foundation, the Israel Ministry of Health, the Tolz Foundation, the Israel Cancer Research Fund, the Israel Cancer Association, the Israel Science Foundation, and the Juvenile Diabetes Foundation International.

The Weizmann Institute of Science, in Rehovot, Israel, is one of the world's foremost centers of scientific research and graduate study. Its 2,500 scientists, students, technicians, and engineers pursue basic research in the quest for knowledge and the enhancement of the human condition. New ways of fighting disease and hunger, protecting the environment, and harnessing alternative sources of energy are high priorities.

Weizmann Institute news releases are posted on the World Wide Web at http://www.weizmann.ac.il and also at http://www.eurekalert.org.
-end-


American Committee for the Weizmann Institute of Science

Related Diabetes Articles from Brightsurf:

New diabetes medication reduced heart event risk in those with diabetes and kidney disease
Sotagliflozin - a type of medication known as an SGLT2 inhibitor primarily prescribed for Type 2 diabetes - reduces the risk of adverse cardiovascular events for patients with diabetes and kidney disease.

Diabetes drug boosts survival in patients with type 2 diabetes and COVID-19 pneumonia
Sitagliptin, a drug to lower blood sugar in type 2 diabetes, also improves survival in diabetic patients hospitalized with COVID-19, suggests a multicenter observational study in Italy.

Making sense of diabetes
Throughout her 38-year nursing career, Laurel Despins has progressed from a bedside nurse to a clinical nurse specialist and has worked in medical, surgical and cardiac intensive care units.

Helping teens with type 1 diabetes improve diabetes control with MyDiaText
Adolescence is a difficult period of development, made more complex for those with Type 1 diabetes mellitus (T1DM).

Diabetes-in-a-dish model uncovers new insights into the cause of type 2 diabetes
Researchers have developed a novel 'disease-in-a-dish' model to study the basic molecular factors that lead to the development of type 2 diabetes, uncovering the potential existence of major signaling defects both inside and outside of the classical insulin signaling cascade, and providing new perspectives on the mechanisms behind insulin resistance in type 2 diabetes and possibly opportunities for the development of novel therapeutics for the disease.

Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.

Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.

Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).

Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.

People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.

Read More: Diabetes News and Diabetes Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.